Atmo Biosciences signs deal with RMIT University to commercialize ingestible gas-sensing capsule for gut health
Atmo Biosciences has signed a licensing deal with RMIT University securing the exclusive worldwide rights to commercialize a ground-breaking ingestible gas-sensing capsule.
The Atmo Gas Capsule is set to revolutionize how doctors diagnose and treat common gastrointestinal (GI) disorders by offering a non-invasive, low-cost, and more accurate alternative to current technologies.
Patients with gut problems will be able to swallow the capsule – about the size of a vitamin pill – and get real time, continuous detection and measurement of hydrogen, methane, and oxygen in the gut. The data can be sent via a handheld receiver and mobile app to the cloud, where it can be analyzed to gain insight into gastrointestinal disorders including small intestinal bacterial overgrowth (SIBO), irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), carbohydrate malabsorption and intolerance.
Atmo Biosciences CEO Mal Hebblewhite said he expected strong demand for the capsule, which is expected to be on the market by 2022.
“One in five people worldwide suffer from a gastrointestinal disorder in their lifetime, and almost a third of these cases remain unresolved, often due to difficulty in diagnosis,” Mal said.
“The Atmo Gas Capsule has the potential to close this gap by offering the ability to identify previously undiagnosed conditions. This will provide relief to the millions of patients who suffer daily without targeted therapy to relieve their symptoms.”
The capsule has already undergone Phase 1 human trials, with results revealing the capsule to be 3,000 times more accurate than breath tests in detecting gas biomarkers.
Capsule co-inventor Dr Kyle Berean, Atmo’s Chief Technology Officer, said: “We know breath tests suffer from high rates of false positive and false negative diagnoses and we know that gas concentrations in the gut are up to 10,000 times higher than those in the breath. By measuring the hydrogen and oxygen produced by the gut directly at the source, our capsule offers vastly more accurate results and unprecedented signal to noise ratios, compared with breath testing.”
Atmo is currently undertaking a series A capital raise, with significant interest in investment and collaboration from global pharma companies and other corporate and strategic partners.
The next stage of development will include Phase 2 human trials, as well as work to enhance the existing technology and expand the range of gases the capsule can sense. Among other indications, researchers will target biomarkers related to ulcerative colitis, a form of inflammatory bowel disease that costs the US healthcare system $US19 billion each year.
Related news
-
Recruitment of the smallest infants in the Connection study paused
IBT started to recruit infants in Strata A (weight of 500g-749g) in The Connection Study on April 29 2021. Today, 68 infants have been recruited to the group. In accordance with the study protocol and clinical observations, enrolment of infants to Strata A has been paused awaiting a safety review by the Data Monitoring Committee (DMC). Subjects already randomized will continue treatment as per protocol, and enrolment of subjects into Strata B (750g-1000g) will continue. IBT is awaiting advice from the DMC before...
-
Second Genome Announces Milestone Accomplished in Collaboration with Bayer, Demonstrating Broad Application of Company`s Machine Learning Platform to Identify Novel Proteins for the Development of Next-Generation Insect-Control Solutions
Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers from public and proprietary microbiome data, today announced it has achieved a milestone in its multi-year collaboration with Bayer to discover proteins for potential development of next-generation insect-control products. “We are pleased to demonstrate successful execution of our collaboration with Bayer and the versatile application of our sg-4sight discovery...
-
Second Genome Presents Preclinical Data Demonstrating the Effects of Microbial-Derived Metabolites in Autism Spectrum Disorder
Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers based on novel microbial genetic insights, presented data from the largest analysis of microbiome function in Autism Spectrum Disorder (ASD), as well as preclinical activity of microbially-derived metabolites predicted to be reduced in ASD, during an oral poster presentation entitled, Predicted Metabolites from Multiple Microbiome Sequencing Datasets Modulate Autism...
-
Atmo Biosciences’ ingestible gas-sensing capsule to be used in Swedish IBS trial led by Professor Magnus Simrén
Atmo Biosciences’ world-first ingestible gas-sensing capsule is being used in a clinical trial led by renowned gastroenterologist Professor Magnus Simrén currently underway at Sweden’s University of Gothenburg. The trial named “The effects of carbohydrates in irritable bowel syndrome” is using the Atmo Gas Capsule digital biomarker platform to profile gases within the gut to help understand the mechanisms and benefits of carbohydrates in people with Irritable Bowel Syndrome (IBS),...
-
Lilly`s Mirikizumab Helps Patients Achieve Clinical Remission and Improves Symptoms in Adults with Ulcerative Colitis in 12-Week Phase 3 Induction Study
Eli Lilly and Company (NYSE: LLY) announced today that mirikizumab met the primary and all key secondary endpoints in LUCENT-1, a 12-week Phase 3 induction study evaluating the efficacy and safety of mirikizumab for the treatment of patients with moderate to severe ulcerative colitis (UC). LUCENT-2, a multicenter, randomized, double-blind, placebo-controlled maintenance study of mirikizumab in patients who have completed the 12-week LUCENT-1 induction study is ongoing. UC is a chronic inflammatory disease of the...
Customer comments
No comments were found for Atmo Biosciences signs deal with RMIT University to commercialize ingestible gas-sensing capsule for gut health. Be the first to comment!